Caden Capital Partners LP Sells 25,026 Shares of Danaher Corporation $DHR

Caden Capital Partners LP lowered its position in shares of Danaher Corporation (NYSE:DHR) by 12.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 172,328 shares of the conglomerate’s stock after selling 25,026 shares during the quarter. Danaher makes up about 13.8% of Caden Capital Partners LP’s holdings, making the stock its 2nd largest holding. Caden Capital Partners LP’s holdings in Danaher were worth $34,166,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. WFA of San Diego LLC purchased a new stake in shares of Danaher during the second quarter worth approximately $26,000. Howard Hughes Medical Institute purchased a new position in Danaher in the 2nd quarter valued at $27,000. ANTIPODES PARTNERS Ltd acquired a new stake in Danaher during the 3rd quarter worth $27,000. TruNorth Capital Management LLC acquired a new stake in Danaher during the 3rd quarter worth $28,000. Finally, Tripletail Wealth Management LLC purchased a new stake in shares of Danaher during the third quarter worth $31,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the transaction, the executive vice president directly owned 5,099 shares in the company, valued at approximately $1,060,642.99. This represents a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.6%

Shares of DHR opened at $187.34 on Friday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $242.80. The firm has a market capitalization of $132.47 billion, a P/E ratio of 37.17, a P/E/G ratio of 2.54 and a beta of 0.93. The firm has a 50-day moving average price of $218.79 and a 200 day moving average price of $215.41. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 27th. The conglomerate reported $2.23 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. The company had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a net margin of 14.71% and a return on equity of 10.81%. Danaher’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.14 earnings per share. Sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.32. Danaher’s dividend payout ratio is presently 25.40%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DHR shares. Weiss Ratings reissued a “hold (c)” rating on shares of Danaher in a research note on Monday, December 29th. JPMorgan Chase & Co. upped their price objective on shares of Danaher from $270.00 to $275.00 and gave the company an “overweight” rating in a research note on Thursday, January 29th. Morgan Stanley assumed coverage on shares of Danaher in a report on Monday, December 1st. They issued an “overweight” rating and a $270.00 price objective for the company. HSBC raised their target price on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Finally, TD Cowen restated a “buy” rating on shares of Danaher in a research report on Wednesday, January 7th. Nineteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $253.55.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.